FundLens
28
Pharma & HealthcareAvoid

ITI Pharma And Healthcare

ITI · Direct–Growth · rank #17 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
17.1%
+16.3% vs index
3 Years
19.9%
+8.3% vs index
5 Years
15.6%
+5.5% vs index
Since launch
15.4%

Year-by-year performance

last entry = YTD
2022
-6.7%
2023
+34.4%
2024
+44.0%
2025
-8.2%
2026
+20.6%

Why this score

ITI Pharma And Healthcare scores 28/100 — #17 of 19 Pharma & Healthcare fund (Avoid). It stands out for expense ratio — beating 86% of peers on expense ratio. The main drag is its 3y return (better than only 21% of peers).

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

3Y return19.86% · 21st percentile in category
5Y return15.60% · 25th percentile in category
Volatility16.53 · 9th percentile in category
Alpha0.31 · 3rd percentile in category
Expense ratio0.89% · 86th percentile in category
Fund size266.74 Cr · 13th percentile in category

Top holdings

top 5 = 37.1% of portfolio
1.Sun Pharmaceutical Industries Ltd11.67%
2.Divi's Laboratories Ltd9.98%
3.Apollo Hospitals Enterprise Ltd5.62%
4.Dr. Reddy's Laboratories Ltd5.23%
5.Torrent Pharmaceuticals Ltd4.58%

37 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds